Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Iron-Deficiency Anemia HELP
Based on 4,751 articles published since 2009

These are the 4751 published articles about Anemia, Iron-Deficiency that originated from Worldwide during 2009-2019.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. 2019

Mueller, Markus M / Van Remoortel, Hans / Meybohm, Patrick / Aranko, Kari / Aubron, Cécile / Burger, Reinhard / Carson, Jeffrey L / Cichutek, Klaus / De Buck, Emmy / Devine, Dana / Fergusson, Dean / Folléa, Gilles / French, Craig / Frey, Kathrine P / Gammon, Richard / Levy, Jerrold H / Murphy, Michael F / Ozier, Yves / Pavenski, Katerina / So-Osman, Cynthia / Tiberghien, Pierre / Volmink, Jimmy / Waters, Jonathan H / Wood, Erica M / Seifried, Erhard / Anonymous3161101. ·German Red Cross Blood Transfusion Service and Goethe University Clinics, Frankfurt/Main, Germany. · Centre for Evidence-Based Practice (CEBaP), Belgian Red Cross, Mechelen, Belgium. · Department of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Frankfurt/Main, Germany. · European Blood Alliance (EBA), Amsterdam, the Netherlands. · Departments of Intensive Care and of Anesthesia, University Hospital of Brest, Brest, France. · Robert-Koch-Institut (RKI), Berlin, Germany. · Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey. · Paul-Ehrlich-Institut (PEI), Langen, Germany. · Department of Public Health and Primary Care, Faculty of Medicine, KU Leuven, Leuven, Belgium. · Canadian Blood Services, Ottawa, Ontario, Canada. · Departments of Medicine, Surgery, Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada. · Société Française de Transfusion Sanguine (SFTS), Paris, France. · Intensive Care, Western Health, Melbourne, Australia. · Fairview Health Services, Minneapolis, Minnesota. · OneBlood, Orlando, Florida. · Department of Cardiothoracic Intensive Care Medicine, Duke University Medical Centre, Durham, North Carolina. · National Health Service Blood and Transplant and University of Oxford, Oxford, United Kingdom. · St. Michael's Hospital and University of Toronto, Toronto, Canada. · Sanquin Blood Bank, Leiden and Department of Haematology, Groene Hart Hospital, Gouda, the Netherlands. · International Society of Blood Transfusion (ISBT), Amsterdam, the Netherlands. · Etablissement Français du Sang (EFS), Saint-Denis, France. · Department of Clinical Epidemiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa. · Departments of Anesthesiology and Bioengineering, University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania. · Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. ·JAMA · Pubmed #30860564.

ABSTRACT: Importance: Blood transfusion is one of the most frequently used therapies worldwide and is associated with benefits, risks, and costs. Objective: To develop a set of evidence-based recommendations for patient blood management (PBM) and for research. Evidence Review: The scientific committee developed 17 Population/Intervention/Comparison/Outcome (PICO) questions for red blood cell (RBC) transfusion in adult patients in 3 areas: preoperative anemia (3 questions), RBC transfusion thresholds (11 questions), and implementation of PBM programs (3 questions). These questions guided the literature search in 4 biomedical databases (MEDLINE, EMBASE, Cochrane Library, Transfusion Evidence Library), searched from inception to January 2018. Meta-analyses were conducted with the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology and the Evidence-to-Decision framework by 3 panels including clinical and scientific experts, nurses, patient representatives, and methodologists, to develop clinical recommendations during a consensus conference in Frankfurt/Main, Germany, in April 2018. Findings: From 17 607 literature citations associated with the 17 PICO questions, 145 studies, including 63 randomized clinical trials with 23 143 patients and 82 observational studies with more than 4 million patients, were analyzed. For preoperative anemia, 4 clinical and 3 research recommendations were developed, including the strong recommendation to detect and manage anemia sufficiently early before major elective surgery. For RBC transfusion thresholds, 4 clinical and 6 research recommendations were developed, including 2 strong clinical recommendations for critically ill but clinically stable intensive care patients with or without septic shock (recommended threshold for RBC transfusion, hemoglobin concentration <7 g/dL) as well as for patients undergoing cardiac surgery (recommended threshold for RBC transfusion, hemoglobin concentration <7.5 g/dL). For implementation of PBM programs, 2 clinical and 3 research recommendations were developed, including recommendations to implement comprehensive PBM programs and to use electronic decision support systems (both conditional recommendations) to improve appropriate RBC utilization. Conclusions and Relevance: The 2018 PBM International Consensus Conference defined the current status of the PBM evidence base for practice and research purposes and established 10 clinical recommendations and 12 research recommendations for preoperative anemia, RBC transfusion thresholds for adults, and implementation of PBM programs. The relative paucity of strong evidence to answer many of the PICO questions supports the need for additional research and an international consensus for accepted definitions and hemoglobin thresholds, as well as clinically meaningful end points for multicenter trials.

2 Guideline [Deficiencia de hierro y anemia ferropénica. Guía para su prevención, diagnóstico y tratamiento. 2017

Anonymous761029 / Anonymous771029 / Anonymous781029. · ·Arch Argent Pediatr · Pubmed #28737884.

ABSTRACT: -- No abstract --

3 Guideline [Iron deficiency in childhood: recommendations of the French Pediatric Society]. 2017

Tounian, P. ·Service de nutrition et gastroentérologie pédiatriques, hôpital Trousseau, 26, avenue du Dr Arnold-Netter, 75012 Paris, France. Electronic address: p.tounian@aphp.fr. ·Arch Pediatr · Pubmed #28622775.

ABSTRACT: -- No abstract --

4 Guideline The role of endoscopy in the management of suspected small-bowel bleeding. 2017

Anonymous13450873 / Gurudu, Suryakanth R / Bruining, David H / Acosta, Ruben D / Eloubeidi, Mohamad A / Faulx, Ashley L / Khashab, Mouen A / Kothari, Shivangi / Lightdale, Jenifer R / Muthusamy, V Raman / Yang, Julie / DeWitt, John M. · ·Gastrointest Endosc · Pubmed #27374798.

ABSTRACT: -- No abstract --

5 Guideline 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. 2016

Ponikowski, Piotr / Voors, Adriaan A / Anker, Stefan D / Bueno, Héctor / Cleland, John G F / Coats, Andrew J S / Falk, Volkmar / González-Juanatey, José Ramón / Harjola, Veli-Pekka / Jankowska, Ewa A / Jessup, Mariell / Linde, Cecilia / Nihoyannopoulos, Petros / Parissis, John T / Pieske, Burkert / Riley, Jillian P / Rosano, Giuseppe M C / Ruilope, Luis M / Ruschitzka, Frank / Rutten, Frans H / van der Meer, Peter / Anonymous6630868. · ·Eur Heart J · Pubmed #27206819.

ABSTRACT: -- No abstract --

6 Guideline Screening for Iron Deficiency Anemia and Iron Supplementation in Pregnant Women to Improve Maternal Health and Birth Outcomes: Recommendation Statement. 2016

Anonymous100860. · ·Am Fam Physician · Pubmed #26926411.

ABSTRACT: -- No abstract --

7 Guideline Screening for Iron Deficiency Anemia in Young Children: USPSTF Recommendation Statement. 2015

Siu, Albert L / Anonymous7640841. · ·Pediatrics · Pubmed #26347426.

ABSTRACT: DESCRIPTION: Update of the US Preventive Services Task Force (USPSTF) 2006 recommendation on screening for iron deficiency anemia. METHODS: The USPSTF reviewed the evidence on the association between change in iron status as a result of intervention and improvement in child health outcomes, as well as screening for and treatment of iron deficiency anemia with oral iron formulations, in children ages 6 to 24 months. POPULATION: This recommendation applies to children ages 6 to 24 months living in the United States who are asymptomatic for iron deficiency anemia. It does not apply to children younger than age 6 months or older than 24 months, children who are severely malnourished, children who were born prematurely or with low birth weight, or children who have symptoms of iron deficiency anemia. RECOMMENDATION: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for iron deficiency anemia in children ages 6 to 24 months. (I statement).

8 Guideline Screening for Iron Deficiency Anemia and Iron Supplementation in Pregnant Women to Improve Maternal Health and Birth Outcomes: U.S. Preventive Services Task Force Recommendation Statement. 2015

Siu, Albert L / Anonymous7090841. · ·Ann Intern Med · Pubmed #26344176.

ABSTRACT: DESCRIPTION: Update of the 2006 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for iron deficiency anemia. METHODS: The USPSTF reviewed the evidence on the association between change in iron status as a result of intervention (oral supplementation or treatment) in pregnant women and adolescents and improvement in maternal and infant health outcomes. POPULATION: This recommendation applies to pregnant women and adolescents living in the United States who do not have symptoms of iron deficiency anemia. It does not address pregnant women who are malnourished, have symptoms of iron deficiency anemia, or have special hematologic conditions or nutritional needs that may increase their need for iron. RECOMMENDATIONS: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for iron deficiency anemia in pregnant women to prevent adverse maternal health and birth outcomes. (I statement). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of routine iron supplementation for pregnant women to prevent adverse maternal health and birth outcomes. (I statement).

9 Guideline Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. 2015

Pennazio, Marco / Spada, Cristiano / Eliakim, Rami / Keuchel, Martin / May, Andrea / Mulder, Chris J / Rondonotti, Emanuele / Adler, Samuel N / Albert, Joerg / Baltes, Peter / Barbaro, Federico / Cellier, Christophe / Charton, Jean Pierre / Delvaux, Michel / Despott, Edward J / Domagk, Dirk / Klein, Amir / McAlindon, Mark / Rosa, Bruno / Rowse, Georgina / Sanders, David S / Saurin, Jean Christophe / Sidhu, Reena / Dumonceau, Jean-Marc / Hassan, Cesare / Gralnek, Ian M. ·Division of Gastroenterology, San Giovanni Battista University Teaching Hospital, Turin, Italy. · Digestive Endoscopy Unit, Catholic University, Rome, Italy. · Department of Gastroenterology, Chaim Sheba Medical Center, Sackler School of Medicine, Tel-Aviv University Tel-Hashomer, Israel. · Klinik für Innere Medizin, Bethesda Krankenhaus Bergedorf, Hamburg, Germany. · Department of Medicine II, Sana Klinikum, Offenbach, Germany. · Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, The Netherlands. · Gastroenterology Unit, Ospedale Valduce, Como, Italy. · Division of Gastroenterology, Shaare Zedek Medical Center, Jerusalem, Israel. · Department of Medicine I, Johann Wolfgang Goethe University Frankfurt, Frankfurt, Germany. · Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Service d'Hépato-gastro-entérologie, Paris, France. · Medizinische Klinik, Evangelisches Krankenhaus, Düsseldorf, Germany. · Department of Hepato-Gastroenterology, Nouvel Hôpital Civil, University Hospital of Strasbourg, Strasbourg, France. · Royal Free Unit for Endoscopy and Centre for Gastroenterology, The Royal Free Hospital and University College London, London, UK. · Department of Medicine B, University of Münster, Münster, Germany. · Institute of Gastroenterology and Liver Diseases, Ha'emek Medical Center Afula, Israel, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology Haifa, Israel. · Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. · Gastroenterology Department, Centro Hospitalar do Alto Ave, Guimarães, Portugal. · Clinical Psychology Unit, Department of Psychology, University of Sheffield. · Centre Hospitalier Lyon Sud, Pierre Bénite, Lyon, France. · Gedyt Endoscopy Center, Buenos Aires, Argentina. ·Endoscopy · Pubmed #25826168.

ABSTRACT: This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). The Guideline was also reviewed and endorsed by the British Society of Gastroenterology (BSG). It addresses the roles of small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders. Main recommendations 1 ESGE recommends small-bowel video capsule endoscopy as the first-line investigation in patients with obscure gastrointestinal bleeding (strong recommendation, moderate quality evidence). 2 In patients with overt obscure gastrointestinal bleeding, ESGE recommends performing small-bowel capsule endoscopy as soon as possible after the bleeding episode, optimally within 14 days, in order to maximize the diagnostic yield (strong recommendation, moderate quality evidence). 3 ESGE does not recommend the routine performance of second-look endoscopy prior to small-bowel capsule endoscopy; however whether to perform second-look endoscopy before capsule endoscopy in patients with obscure gastrointestinal bleeding or iron-deficiency anaemia should be decided on a case-by-case basis (strong recommendation, low quality evidence). 4 In patients with positive findings at small-bowel capsule endoscopy, ESGE recommends device-assisted enteroscopy to confirm and possibly treat lesions identified by capsule endoscopy (strong recommendation, high quality evidence). 5 ESGE recommends ileocolonoscopy as the first endoscopic examination for investigating patients with suspected Crohn's disease (strong recommendation, high quality evidence). In patients with suspected Crohn's disease and negative ileocolonoscopy findings, ESGE recommends small-bowel capsule endoscopy as the initial diagnostic modality for investigating the small bowel, in the absence of obstructive symptoms or known stenosis (strong recommendation, moderate quality evidence).ESGE does not recommend routine small-bowel imaging or the use of the PillCam patency capsule prior to capsule endoscopy in these patients (strong recommendation, low quality evidence). In the presence of obstructive symptoms or known stenosis, ESGE recommends that dedicated small bowel cross-sectional imaging modalities such as magnetic resonance enterography/enteroclysis or computed tomography enterography/enteroclysis should be used first (strong recommendation, low quality evidence). 6 In patients with established Crohn's disease, based on ileocolonoscopy findings, ESGE recommends dedicated cross-sectional imaging for small-bowel evaluation since this has the potential to assess extent and location of any Crohn's disease lesions, to identify strictures, and to assess for extraluminal disease (strong recommendation, low quality evidence). In patients with unremarkable or nondiagnostic findings from such cross-sectional imaging of the small bowel, ESGE recommends small-bowel capsule endoscopy as a subsequent investigation, if deemed to influence patient management (strong recommendation, low quality evidence). When capsule endoscopy is indicated, ESGE recommends use of the PillCam patency capsule to confirm functional patency of the small bowel (strong recommendation, low quality evidence). 7 ESGE strongly recommends against the use of small-bowel capsule endoscopy for suspected coeliac disease but suggests that capsule endoscopy could be used in patients unwilling or unable to undergo conventional endoscopy (strong recommendation, low quality evidence).

10 Guideline European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. 2015

Dignass, Axel U / Gasche, Christoph / Bettenworth, Dominik / Birgegård, Gunnar / Danese, Silvio / Gisbert, Javier P / Gomollon, Fernando / Iqbal, Tariq / Katsanos, Konstantinos / Koutroubakis, Ioannis / Magro, Fernando / Savoye, Guillaume / Stein, Jürgen / Vavricka, Stephan / Anonymous4220815. ·Department of Medicine 1, Agaplesion Markus Hospital, Frankfurt, Germany Crohn Colitis Center, Frankfurt, Germany [*AD and *CG are both [shared] first authors and acted as conveners of the Consensus]. axel.dignass@fdk.info. · Department of Medicine 3, Medical University of Vienna, Austria [*AD and *CG are both [shared] first authors and acted as conveners of the Consensus]. · Department of Medicine B, University of Münster, Münster, Germany. · Department of Hematology, Institute of Medical Sciences, Uppsala University Uppsala, Sweden. · Istituto Clinico Humanitas, Rozanno, Milan, Italy. · Department of Gastroenterology, Hospital Universitario de la Princesa, IP and CIBEREHD, Madrid, Spain. · Hospital Clinico Universitario, CIBEREHD, Zaragoza, Spain. · University Hospitals Birmingham, NHS Foundation Trust, Birmingham, UK. · First Department of Internal Medicine, University Hospital of Ioannina, Ioannina, Greece. · University Hospital Heraklion, Heraklion, Crete, Greece. · Sao Joao Hospital, Porto, Portugal. · Rouen University Hospital, Rouen, France. · Crohn Colitis Center, Frankfurt, Germany. ·J Crohns Colitis · Pubmed #25518052.

ABSTRACT: -- No abstract --

11 Guideline [Statement of the Polish Gynecological Society Expert Group on the prevention of iron deficiency and of anemia caused by iron deficiency with a low dose heme iron in women. State of the art, 2013]. 2014

Anonymous1900784. · ·Ginekol Pol · Pubmed #24505970.

ABSTRACT: -- No abstract --

12 Guideline Treatment of anemia in patients with heart disease: a clinical practice guideline from the American College of Physicians. 2013

Qaseem, Amir / Humphrey, Linda L / Fitterman, Nick / Starkey, Melissa / Shekelle, Paul / Anonymous4030777. ·From the American College of Physicians, Philadelphia, Pennsylvania; Oregon Health and Science University, Portland, Oregon; Huntington Hospital, Pasadena, California; and West Los Angeles Veteran Affairs Medical Center, Los Angeles, California. ·Ann Intern Med · Pubmed #24297193.

ABSTRACT: DESCRIPTION: The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the treatment of anemia and iron deficiency in adult patients with heart disease. METHODS: This guideline is based on published literature in the English language on anemia and iron deficiency from 1947 to July 2012 that was identified using MEDLINE and the Cochrane Library. Literature was reassessed in April 2013, and additional studies were included. Outcomes evaluated for this guideline included mortality; hospitalization; exercise tolerance; quality of life; and cardiovascular events (defined as myocardial infarction, congestive heart failure exacerbation, arrhythmia, or cardiac death) and harms, including hypertension, venous thromboembolic events, and ischemic cerebrovascular events. The target audience for this guideline includes all clinicians, and the target patient population is anemic or iron-deficient adult patients with heart disease. This guideline grades the evidence and recommendations using the ACP's clinical practice guidelines grading system. RECOMMENDATION 1: ACP recommends using a restrictive red blood cell transfusion strategy (trigger hemoglobin threshold of 7 to 8 g/dL compared with higher hemoglobin levels) in hospitalized patients with coronary heart disease. (Grade: weak recommendation; low-quality evidence) RECOMMENDATION 2: ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease. (Grade: strong recommendation; moderate-quality evidence).

13 Guideline Guideline for the laboratory diagnosis of functional iron deficiency. 2013

Thomas, D Wayne / Hinchliffe, Rod F / Briggs, Carol / Macdougall, Iain C / Littlewood, Tim / Cavill, Ivor / Anonymous2330755. ·Derriford Hospital, Plymouth, UK. ·Br J Haematol · Pubmed #23573815.

ABSTRACT: -- No abstract --

14 Guideline [Statement of the Polish Gynecological Society Expert Group on the use of iron preparations (Tardyferon, Tardyferon-Fol) in obstetrics and gynaecology]. 2013

Anonymous5030752. · ·Ginekol Pol · Pubmed #23488315.

ABSTRACT: According to the literature data, approximately 700 million people worldwide have overt or latent iron deficiency This is related to nutrition. The highest risk groups, apart from children, are pregnant women (50-60%) and young women of childbearing age (20-40%). Anaemia is a hazard for pregnant and parturient women, as well as for the foetus and newborn. In pregnant women, pharmacological treatment should be initiated if parameters such as haemoglobin, iron and ferritin levels indicate existing iron deficiency or overt anaemia. Treatment should be administered in each period of pregnancy Commonly recommended anaemia management includes two actions: a diet rich in iron and therapy with preparations containing iron with folic acid. Oral, well-tolerated and sustained-release iron products are preferred. Formulations containing divalent iron, slowly-absorbed, causing no gastrointestinal intolerance, which are available on the Polish market, include Tardyferon and Tardyferon-Fol. These products fully meet WHO requirements for recommended daily intake of elemental iron in patients with anaemia or iron deficiency In the opinion of the Polish Gynaecological Society Panel of Experts, iron preparations Tardyferon and Tardyferon-Fol are effective therapeutic options for the prevention and treatment of iron deficiency anaemia.

15 Guideline [Review by expert group in the diagnosis and treatment of anemia in pregnant women. Federación Mexicana de Colegios de Obstetricia y Ginecología]. 2012

Montoya Romero, Jose de Jesús / Castelazo Morales, Ernesto / Valerio Castro, Emilio / Velázquez Cornejo, Gerardo / Nava Muñoz, David Antonio / Escárcega Preciado, Jaime Arturo / Montoya Cossío, Javier / Pichardo Villalón, Guadalupe Mireya / Maldonado Aragón, Aristeo / Santana García, Héctor Rogelio / Fajardo Dueñas, Sergio / Mondragón Galindo, César Germán / García Lee, Teresa / García, Angel / Hernández de Morán, Marcela / Chávez Güitrón, Luis Eduardo / Jiménez Gutiérrez, Carlos / Anonymous930745. ·Federación Mexicana de Colegios de Obstetricia y Ginecologia, A. C. ·Ginecol Obstet Mex · Pubmed #23243836.

ABSTRACT: BACKGROUND: According to data from the World Health Organization and UNICEF from year 2009, iron deficiency is the most widespread nutritional deficiency worldwide. This deficiency causes an imbalance between needs and iron supply, which consequently results in anemia. Around the world, two million people suffer from anemia, half of which is due to iron deficiency. The most impacted groups are children and teenagers, due to their highest requirements derived from the growing process, and women in their reproductive age, due to their loss of iron derived from menstruating or to their highest iron needs during pregnancy. This increase in needs is not satisfied by the regular diet, since it includes an insufficient amount and/or low bioavailability of iron. PURPOSE: To share with the medical community treating pregnant women the experience of an expert group so that they always bear in mind the repercussions caused by anemia during pregnancy, know more about the diagnostic possibilities and have a reference point for prescribing iron supplements. METHOD: The consensus method was used through the expert panel group technique. Two rounds were taken for structuring the clinical questions. The first one was to facilitate working groups their focusing in the clinical topics and the population of interest; the second one was to aid in posing specific questions observing the Patient, Intervention, Compare and Outcome (PICO) structure. The primary and clinical secondary study variables were defined by the working groups from the previously developed questions and during the face-to-face working period, according to the natural history of the disease: risk factors, diagnostic classification, (either pharmacological or non pharmacological) treatment and prognosis. The level of evidence and clinical recommendation was classified based on the Evidence Classification Level and Clinical Recommendation of the Medicine Group based on Evidence from Oxford University. RESULTS: In Mexico, 20.6% of pregnant women suffer from anemia, especially those between 15 and 16 years old, who prevail in 42.4% and 34.3% percent, respectively. Almost half the cases are due to iron deficiency. This type of anemia is associated with a higher risk of pre-term delivery, of low birth weight and perinatal death. The first assessment of an anemic pregnant woman shall include the medical history, a physical examination and the quantification of the erythrocyte indices, serum concentrations of iron and ferritin. The measurement of this last one has the highest sensitivity and specificity for diagnosing iron deficiency. Daily oral iron supplementation, at a 60-to-120 mg dosage, may correct most of mild-to-moderate anemias. The most appropriate treatment is with iron salts (iron sulfate, polimaltose iron complex or iron fumarate). In case of intolerance to iron sulfate or fumarate, polimaltose iron is a better tolerated option. Treatment shall be administered until the hemoglobin values are > 10.5 g and ferritin is between 300 and 360 microg/dL, and such levels shall be observed for at least one year. Parenteral administration is an alternative for patients with a severe intolerance to oral administration; even when the possibility of anaphylaxis shall be considered it is lower when using ferrous sacarate. Transfusion is reserved for patients with hemoglobin lower than 7 g/dL or having an imminent cardio-respiratory decompensation. CONCLUSIONS: Iron deficiency is the highest prevailing nutritional deficiency worldwide and its consequences during pregnancy may be highly risky for both the mother and her child. Anemia diagnosis may easily be achieved through a blood analysis including the serum ferritin determination. Serum iron measurement shall not be used as the only marker to set the diagnosis. It is important to rule out other causes, in addition to the deficiencies, which produce anemia in a patient. It is essential to suggest the administration of iron supplements not only during the antenatal period but also after birth o even after a miscarriage to fulfill the need for depleted iron. In severe anemias (hemoglobin being lower than 9.0 g/L), iron doses higher than 120 mg a day may be required. Treatment shall always begin orally, and if this is not well tolerated, parenteral administration shall be used.

16 Guideline Committee Opinion No.543: Timing of umbilical cord clamping after birth. 2012

Anonymous4780742. · ·Obstet Gynecol · Pubmed #23168790.

ABSTRACT: The optimal timing for clamping the umbilical cord after birth has been a subject of controversy and debate. Although many randomized controlled trials in term and preterm infants have evaluated the benefits of delayed umbilical cord clamping versus immediate umbilical cord clamping, the ideal timing for cord clamping has yet to be established. Several systematic reviews have suggested that clamping the umbilical cord in all births should be delayed for at least 30-60 seconds, with the infant maintained at or below the level of the placenta because of the associated neonatal benefits, including increased blood volume, reduced need for blood transfusion, decreased incidence of intracranial hemorrhage in preterm infants, and lower frequency of iron deficiency anemia in term infants. Evidence exists to support delayed umbilical cord clamping in preterm infants, when feasible. The single most important clinical benefit for preterm infants is the possibility for a nearly 50% reduction in intraventricular hemorrhage. However, currently, evidence is insufficient to confirm or refute the potential for benefits from delayed umbilical cord clamping in term infants, especially in settings with rich resources.

17 Guideline UK guidelines on the management of iron deficiency in pregnancy. 2012

Pavord, Sue / Myers, Bethan / Robinson, Susan / Allard, Shubha / Strong, Jane / Oppenheimer, Christina / Anonymous2251292. ·University Hospitals of Leicester. bcsh@b-s-h.org.uk ·Br J Haematol · Pubmed #22512001.

ABSTRACT: Iron deficiency is the most common deficiency state in the world, affecting more than 2 billion people globally. Although it is particularly prevalent in less-developed countries, it remains a significant problem in the developed world, even where other forms of malnutrition have already been almost eliminated. Effective management is needed to prevent adverse maternal and pregnancy outcomes, including the need for red cell transfusion. The objective of this guideline is to provide healthcare professionals with clear and simple recommendations for the diagnosis, treatment and prevention of iron deficiency in pregnancy and the postpartum period. This is the first such guideline in the UK and may be applicable to other developed countries. Public health measures, such as helminth control and iron fortification of foods, which can be important to developing countries, are not considered here. The guidance may not be appropriate to all patients and individual patient circumstances may dictate an alternative approach.

18 Guideline [Expert panel recommendations Polish Gynecological Society for preparations Femibion Natal 1, Femibion Natal 2 and Femibion Vita Ferr]. 2012

Anonymous5350719. · ·Ginekol Pol · Pubmed #22384644.

ABSTRACT: -- No abstract --

19 Guideline Guidelines for the management of iron deficiency anaemia. 2011

Goddard, Andrew F / James, Martin W / McIntyre, Alistair S / Scott, Brian B / Anonymous1610694. ·Digestive Diseases Centre, Royal Derby Hospital, Derby, UK ·Gut · Pubmed #21561874.

ABSTRACT: BACKGROUND: Iron deficiency anaemia (IDA) occurs in 2-5% of adult men and postmenopausal women in the developed world and is a common cause of referral to gastroenterologists. Gastrointestinal (GI) blood loss from colonic cancer or gastric cancer, and malabsorption in coeliac disease are the most important causes that need to be sought. DEFINING IRON DEFICIENCY ANAEMIA: The lower limit of the normal range for the laboratory performing the test should be used to define anaemia (B). Any level of anaemia should be investigated in the presence of iron deficiency (B). The lower the haemoglobin the more likely there is to be serious underlying pathology and the more urgent is the need for investigation (B). Red cell indices provide a sensitive indication of iron deficiency in the absence of chronic disease or haemoglobinopathy (A). Haemoglobin electrophoresis is recommended when microcytosis and hypochromia are present in patients of appropriate ethnic background to prevent unnecessary GI investigation (C). Serum ferritin is the most powerful test for iron deficiency (A). INVESTIGATIONS: Upper and lower GI investigations should be considered in all postmenopausal female and all male patients where IDA has been confirmed unless there is a history of significant overt non-GI blood loss (A). All patients should be screened for coeliac disease (B). If oesophagogastroduodenoscopy (OGD) is performed as the initial GI investigation, only the presence of advanced gastric cancer or coeliac disease should deter lower GI investigation (B). In patients aged >50 or with marked anaemia or a significant family history of colorectal carcinoma, lower GI investigation should still be considered even if coeliac disease is found (B). Colonoscopy has advantages over CT colography for investigation of the lower GI tract in IDA, but either is acceptable (B). Either is preferable to barium enema, which is useful if they are not available. Further direct visualisation of the small bowel is not necessary unless there are symptoms suggestive of small bowel disease, or if the haemoglobin cannot be restored or maintained with iron therapy (B). In patients with recurrent IDA and normal OGD and colonoscopy results, Helicobacter pylori should be eradicated if present. (C). Faecal occult blood testing is of no benefit in the investigation of IDA (B). All premenopausal women with IDA should be screened for coeliac disease, but other upper and lower GI investigation should be reserved for those aged 50 years or older, those with symptoms suggesting gastrointestinal disease, and those with a strong family history of colorectal cancer (B). Upper and lower GI investigation of IDA in post-gastrectomy patients is recommended in those over 50 years of age (B). In patients with iron deficiency without anaemia, endoscopic investigation rarely detects malignancy. Such investigation should be considered in patients aged >50 after discussing the risk and potential benefit with them (C). Only postmenopausal women and men aged >50 years should have GI investigation of iron deficiency without anaemia (C). Rectal examination is seldom contributory, and, in the absence of symptoms such as rectal bleeding and tenesmus, may be postponed until colonoscopy. Urine testing for blood is important in the examination of patients with IDA (B). MANAGEMENT: All patients should have iron supplementation both to correct anaemia and replenish body stores (B). Parenteral iron can be used when oral preparations are not tolerated (C). Blood transfusions should be reserved for patients with or at risk of cardiovascular instability due to the degree of their anaemia (C).

20 Guideline Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. 2010

Marret, H / Fauconnier, A / Chabbert-Buffet, N / Cravello, L / Golfier, F / Gondry, J / Agostini, A / Bazot, M / Brailly-Tabard, S / Brun, J-L / De Raucourt, E / Gervaise, A / Gompel, A / Graesslin, O / Huchon, C / Lucot, J-P / Plu-Bureau, G / Roman, H / Fernandez, H / Anonymous3590667. ·Centre Hospitalo-Universitaire de Tours, Hôpital Bretonneau, Service de Gynécologie, Tours 37044 cédex 1, France. marret@med.univ-tours.fr ·Eur J Obstet Gynecol Reprod Biol · Pubmed #20688424.

ABSTRACT: BACKGROUND: Normal menstrual periods last 3-6 days and involve blood loss of up to 80ml. Menorrhagia is defined as menstrual periods lasting more than 7 days and/or involving blood loss greater than 80ml. The prevalence of abnormal uterine bleeding (AUB) is estimated at 11-13% in the general population and increases with age, reaching 24% in those aged 36-40 years. INVESTIGATION: A blood count for red cells+platelets to test for anemia is recommended on a first-line basis for women consulting for AUB whose history and/or bleeding score justify it. A pregnancy test by an hCG assay should be ordered. A speculum examination and Pap smear, according to the French High Health Authority guidelines should be performed early on to rule out any cervical disease. Pelvic ultrasound, both abdominal (suprapubic) and transvaginal, is recommended as a first-line procedure for the etiological diagnosis of AUB. Hysteroscopy or hysterosonography can be suggested as a second-line procedure. MRI is not recommended as a first-line procedure. TREATMENT: In idiopathic AUB, the first-line treatment is medical, with efficacy ranked as follows: levonorgestrel IUD, tranexamic acid, oral contraceptives, either estrogens and progestins or synthetic progestins only, 21 days a month, or NSAIDs. When hormone treatment is contraindicated or immediate pregnancy is desired, tranexamic acid is indicated. Iron must be included for patients with iron-deficiency anemia. For women who do not wish to become pregnant in the future and who have idiopathic AUB, the long-term efficacy of conservative surgical treatment is greater than that of oral medical treatment. Placement of a levonorgestrel IUD (or administration of tranexamic acid by default) is recommended for women with idiopathic AUB. If this fails, a conservative surgical technique must be proposed; the choices include second-generation endometrial ablation techniques (thermal balloon, microwave, radiofrequency), or, if necessary, first-generation techniques (endometrectomy, roller-ball). A first-line hysterectomy is not recommended in this context. Should a hysterectomy be selected for functional bleeding, it should be performed by the vaginal or laparoscopic routes.

21 Guideline [Iron deficiency anemia. Guideline for diagnosis and treatment]. 2009

Anonymous2950638. · ·Arch Argent Pediatr · Pubmed #19753445.

ABSTRACT: Iron deficiency is the most important cause of anemia. Preschooler children are particularly vulnerable; a recent analysis reported a prevalence rate higher than 35% among children below 2 year of age. Its early detection, right treatment, and suitable prophylaxis is currently a priority in our country. This guideline establishes the definition of anemia in relation to chronological age, gestational age, and habitat, reviews principal aspects of iron metabolism, enumerates main causes of iron deficiency, and set guidelines for diagnosis, detection, differential diagnosis, treatment and prevention of iron deficiency anemia.

22 Guideline [Short version of the S3 (level 3) guideline "Helicobacter pylori and gastroduodenal ulcer disease" from the German Society for Digestive and Metabolic Diseases]. 2009

Fischbach, W / Anonymous4210637 / Anonymous4220637 / Anonymous4230637 / Anonymous4240637. ·Medizinische Klinik II und Klinik für Palliativmedizin, Klinikum Aschaffenburg. med2-aschaffenburg@t-online.de ·Dtsch Med Wochenschr · Pubmed #19728254.

ABSTRACT: This guideline updates a prior concensus recommendation of the German Society for Digestive and Metabolic Diseases (DGVS) from 1996. It was developed by an interdisciplinary cooperation with representatives of the German Society for Microbiology, the Society for Pediatric Gastro-enterology and Nutrition (GPGE) and the German Society for Rheumatology. The guideline is methodologically based on recommendations of the Association of the Scientific Medical Societies in Germany (AWMF) for providing a systematic evidence-based consensus guideline of S3 level and has also implemented grading criteria according to GRADE (Grading of Recommendations Assessment, Development and Evaluation). Clinical applicability of study results as well as specifics for Germany in terms of epidemiology, antibiotic resistance status, diagnostics and therapy were taken into account.

23 Editorial Acute heart failure, iron deficiency, and hyperlactataemia: a high-risk combination. 2019

Barge-Caballero, Eduardo / Couto-Mallón, David. ·Complejo Hospitalario Universitario de A Coruña (CHUAC), Instituto de Investigación Biomédica de A Coruña (INIBIC), Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), A Coruña, Spain. Eduardo.Barge.Caballero@sergas.es. · Complejo Hospitalario Universitario de A Coruña (CHUAC), Instituto de Investigación Biomédica de A Coruña (INIBIC), Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), A Coruña, Spain. ·Kardiol Pol · Pubmed #30912109.

ABSTRACT: -- No abstract --

24 Editorial An update on the evaluation and management of iron deficiency anemia in inflammatory bowel disease. 2019

Aksan, Ayşegül / Farrag, Karima / Stein, Jürgen. ·a Crohn Colitis Clinical Research Centre Rhein-Main , Frankfurt am Main , Germany. · b Faculty of Health Sciences , Hacettepe University , Ankara , Turkey. · c Gastroenterology and Clinical Nutrition , DGD Clinics Sachsenhausen , Frankfurt am Main , Germany. · d Department of Pharmaceutical Chemistry , University of Frankfurt , Frankfurt am Main , Germany. ·Expert Rev Gastroenterol Hepatol · Pubmed #30791779.

ABSTRACT: -- No abstract --

25 Editorial When should iron supplementation in dialysis patients be avoided, minimized or withdrawn? 2019

Rostoker, Guy. ·Ramsay-Générale de Santé, Division of Nephrology and Dialysis, Hôpital Privé Claude Galien, Quincy sous Sénart, France. ·Semin Dial · Pubmed #29956370.

ABSTRACT: Parenteral iron is used to restore the body's iron pool before and during erythropoiesis-stimulating agent (ESA) therapy; together these agents form the backbone of anemia management in end-stage renal disease (ESRD) patients undergoing hemodialysis. ESRD patients receiving chronic intravenous iron products, which exceed their blood loss are exposed to an increased risk of positive iron balance. Measurement of the liver iron concentration (LIC) reflects total body iron stores in patients with secondary hemosiderosis and genetic hemochromatosis. Recent studies of LIC in hemodialysis patients, measured by quantitative MRI and magnetic susceptometry, have demonstrated a high risk of iron overload in dialysis patients treated with IV iron products at doses advocated by current anemia management guidelines for dialysis patients. Liver iron overload causes increased production of hepcidin and elevated plasma levels, which can activate macrophages of atherosclerotic plaques. This mechanism may explain the results of 3 long-term epidemiological studies which showed the association of excessive IV iron doses with increased risk of cardiovascular morbidity and mortality among hemodialysis patients. A more physiological approach of iron therapy in ESRD is needed. Peritoneal dialysis patients, hemodialysis patients infected with hepatitis C virus, and hemodialysis patients with ferritin above 1000 μg/L without a concomitant inflammatory state, all require specific and cautious iron management. Two recent studies have shown that most hemodialysis patients will benefit from lower maintenance IV iron dosages; their results are applicable to American hemodialysis patients. Novel pharmacometric and economic approaches to iron therapy and anemia management are emerging which are designed to lessen the potential side effects of excessive IV iron while maintaining hemoglobin stability without an increase in ESA dosing.